MedTrace Logo

The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis

NCT03862859 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 718

Last updated 2026-05-19

No results posted yet for this study

Summary

The study aims to evaluate the appropriateness of initiating oral anticoagulation for stroke risk reduction in dialysis populations with atrial fibrillation. Specifically, the study will assess the overall safety, tolerability, and efficacy of initiating treatment with Warfarin in patients with end-stage renal disease on dialysis and atrial fibrillation.

Conditions

  • Atrial Fibrillation and Flutter
  • Stroke
  • Major Bleed
  • End-stage Renal Disease

Interventions

DRUG

Warfarin

Dose adjusted Warfarin targeting an international normalized ratio of 2-3.

Sponsors & Collaborators

  • Danish Heart Foundation

    collaborator OTHER

  • Nicholas Carlson

    lead OTHER

Principal Investigators

  • Nicholas Carlson, MD PhD · Department of Nephrology, Copenhagen University Hospital Rigshospitalet

  • Anne-Lise Kamper, MD DMSc · Department of Nephrology, Copenhagen University Hospital Rigshospitalet

  • Christian Torp-Pedersen, Prof MD DMSc · Department of Cardiology, North Zealand Hospital

  • Ditte Hansen, MD PhD · Department of Nephrology, Copenhagen University Hospital Herlev

  • Mads Hornum, Prof MD PhD · Department of Nephrology, Copenhagen University Hospital Rigshospitalet

  • Erik Grove, MD PhD · Department of Cardiology, Aarhus University Hospital

  • Ellen Linnea F Ballegaard, MD · Department of Nephrology, Copenhagen University Hospital Rigshospitalet

  • Christian D Peters, MD PhD · Department of Nephrology, Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-09
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03862859 on ClinicalTrials.gov